Research Topics
| Giovanni F M StrippoliSummaryAffiliation: Consorzio Mario Negri Sud Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Depression and sexual dysfunction in chronic kidney disease: a narrative review of the evidence in areas of significant unmet needMariacristina Vecchio
Correspondence and offprint requests to Giovanni F M Strippoli E mail
Nephrol Dial Transplant 27:3420-8. 2012....
Sexual dysfunction in women with ESRD requiring hemodialysisGiovanni F M Strippoli
Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S Maria Imbaro, Italy
Clin J Am Soc Nephrol 7:974-81. 2012..Sexual dysfunction was identified by the Female Sexual Function Index. Correlates of self-reported sexual dysfunction were identified by regression analyses...- Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional studyMariacristina Vecchio
Nephrol Dial Transplant 27:2479-88. 2012.... - Meta-analysis: vitamin D compounds in chronic kidney diseaseSuetonia C Palmer
Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Ann Intern Med 147:840-53. 2007..Vitamin D compounds are widely used to prevent and treat secondary hyperparathyroidism... 
Fluid and nutrient intake and risk of chronic kidney diseaseGiovanni F M Strippoli
Centre for Kidney Research, NHMRC Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, The Children s Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia
Nephrology (Carlton) 16:326-34. 2011..We evaluated the association between fluid and nutrient intake and chronic kidney disease (CKD)...- Haemoglobin targets: we were wrong, time to move onGiovanni F M Strippoli
Cochrane Renal Group and Centre for Kidney Research and NHMRC Centre for Clinical Research Excellence in Renal Medicine, School of Public Health, University of Sydney, Sydney, New South Wales, Australia
Lancet 369:346-50. 2007 - Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocolGiovanni F M Strippoli
Department of Clinical Pharmacology and Epidemiology, Mario Negri Sud Consortium, 66030 S, Maria Imbaro CH, Italy
Trials 11:70. 2010..The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) trial will assess the benefits and harms of a high versus a low fixed ESA dose for the management of anemia in patients with end stage kidney disease... - Antiplatelet agents for chronic kidney diseaseSuetonia C Palmer
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Cochrane Database Syst Rev 2:CD008834. 2013..The risks and benefits of antiplatelet treatment may be different in people with chronic kidney disease (CKD) for whom occlusive atherosclerotic events are less prevalent, and bleeding hazards might be increased... - Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysisSuetonia C Palmer
Department of Medicine, University of Otago, Christchurch, New Zealand
Am J Kidney Dis 61:112-22. 2013..Antiplatelet agents may prevent hemodialysis vascular access failure, but potentially may be hazardous in people with end-stage kidney disease who have impaired hemostasis... - Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysisSuetonia C Palmer
University of Otago, Christchurch, 2 Riccarton Avenue, PO Box 4345, Christchurch 8041, New Zealand
Ann Intern Med 157:263-75. 2012..Statins have uncertain benefits in persons with chronic kidney disease (CKD) because individual trials may have insufficient power to determine whether treatment effects differ with severity of CKD... - Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trialsGiovanni F M Strippoli
NHMRC Centre for Clinical Research Excellence in Renal Medicine, School of Public Health, University of Sydney, Australia
BMJ 336:645-51. 2008..To analyse the benefits and harms of statins in patients with chronic kidney disease (pre-dialysis, dialysis, and transplant populations)... - Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney diseaseSuetonia C Palmer
University of Otago, Christchurch, New Zealand
Ann Intern Med 153:23-33. 2010..Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional randomized trials have been recently completed... - Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsElisabeth M Hodson
Centre for Kidney Research, The Children s Hospital at Westmead, Westmead, Australia
Cochrane Database Syst Rev 2:CD003774. 2013..This is an update of a review first published in 2005 and updated in 2008... - Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysisSuetonia C Palmer
Department of Medicine, University of Otago, Christchurch, New Zealand
JAMA 305:1119-27. 2011..Clinical practice guidelines on the management of mineral and bone disorders due to chronic kidney disease recommend specific treatment target levels for serum phosphorus, parathyroid hormone, and calcium... - Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trialsGiovanni F M Strippoli
NHMRC Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, Locked Bag 4001, University of Sydney, Australia
J Am Soc Nephrol 15:2735-46. 2004.... - Meta-analysis of biochemical and patient-level effects of calcimimetic therapyGiovanni F M Strippoli
NHMRC Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, School of Public Health, University of Sydney, Australia
Am J Kidney Dis 47:715-26. 2006..We conducted a meta-analysis to evaluate outcomes of therapy with these novel agents... - Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trialsMariacristina Vecchio
Department of Clinical Pharmacology and Epidemiology, Mario Negri Sud Consortium, S Maria Imbaro, Italy
Clin J Am Soc Nephrol 5:985-95. 2010..Sexual dysfunction is very common in patients with chronic kidney disease (CKD), but treatment options are limited. The benefits and harms of existing interventions for treatment of sexual dysfunction were assessed in patients with CKD... - Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progressionGiovanni F M Strippoli
National Health and Medical Research Council Centre for Clinical Research Excellence in Renal Medicine, University of Sydney, Australia
J Am Soc Nephrol 17:S153-5. 2006..On the basis of available RCT evidence, ACEi are the only agents with proven renal benefit in patients who have diabetes with no nephropathy and the only agents with proven survival benefit in patients who have diabetes with nephropathy... - Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysisSuetonia C Palmer
University of Otago, Christchurch, New Zealand
Ann Intern Med 156:445-59. 2012.... - Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipientsGiovanni F M Strippoli
NHMRC Centre for Clinical Research Excellence in Renal Medicine, Centre for Kidney Research, The Children s Hospital at Westmead, Sydney, Australia
Transplantation 81:139-45. 2006..This study was conducted to evaluate the efficacy of preemptive treatment in preventing symptomatic CMV disease... - Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trialsGiovanni F M Strippoli
Centre for Kidney Research, NHMRC Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, Locked Bag 4001, The Children s Hospital at Westmead and the University of Sydney, Westmead, NSW 2145, Australia
J Am Soc Nephrol 15:3154-65. 2004..There is insufficient data to guide decisions in patients without cardiovascular disease or in the predialysis population... - Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trialsSuetonia C Palmer
Department of Nephrology, Christchurch Hospital, Christchurch, New Zealand
Am J Kidney Dis 45:638-49. 2005..This study was conducted to assess the evidence available to guide targeted treatment to reduce bone disease in transplant recipients... - Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trialsSuetonia C Palmer
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
PLoS Med 10:e1001436. 2013.... - Antihypertensive agents for primary prevention of diabetic nephropathyGiovanni F M Strippoli
Cochrane Renal Group, Centre for Kidney Research, Locked Bag 4001, Children s Hospital at Westmead, Westmead, NSW 2145, Australia
J Am Soc Nephrol 16:3081-91. 2005.... - How to read a nephrology systematic reviewSuetonia C Palmer
Department of Medicine, University of Otago, Christchurch, New Zealand
Nephrology (Carlton) 15:158-64. 2010..We summarize the features of a systematic review that should be looked for when considering the accuracy and validity of its results - particularly when applying the outcomes of a systematic review to a clinical question... - Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trialsGiorgia De Berardis
Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8 A, 66030 S Maria Imbaro, Italy
BMJ 339:b4531. 2009..To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease... - Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trialsAusilia Maione
Department of Pharmacology and Clinical Epidemiology, Mario Negri Sud Consortium, S Maria Imbaro Ch, Italy
Nephrol Dial Transplant 26:2827-47. 2011..We examined the benefits and risks of these agents in people with albuminuria and one or more cardiovascular risk factors... - High-flux versus low-flux membranes for end-stage kidney diseaseSuetonia C Palmer
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Cochrane Database Syst Rev 9:CD005016. 2012..Clinical practice guidelines regarding the use of high-flux haemodialysis membranes vary widely... - Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic studyMonica Franciosi
Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale, 66030 S Maria Imbaro CH, Italy
Clin J Am Soc Nephrol 2:984-91. 2007..The objective of this study was to investigate correlates of risk for having microalbuminuria in individuals with one or more cardiovascular risk factors... - Is renal impairment a predictor of the incidence of cataract or cataract surgery? Findings from a population-based studySon C Huynh
Centre for Vision Research, Department of Ophthalmology and Westmead Millennium Institute, University of Sydney, Sydney, NSW, Australia
Ophthalmology 112:293-300. 2005..To explore the relationship between creatinine clearance, an estimate of glomerular filtration rate, and 5-year incidence of cataract and cataract surgery... - Risk factors for the development and progression of renal diseases in disadvantaged populations: role of the renin-angiotensin system blockadeAusilia Maione
Mario Negri Sud Consortium, S Maria Imbaro Ch, Italy
Ethn Dis 19:S1-86-9. 2009..It is plausible that these disadvantaged groups may benefit more than others from a renal and cardiovascular prevention program, but considerable under-recognition and under-treatment of these conditions still exist... - Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trialsLorna K Henderson
Cochrane Renal Group, Centre for Kidney Research, The Children s Hospital at Westmead, Sydney, Australia
Am J Kidney Dis 61:74-87. 2013..Treatment regimens combining cyclophosphamide with steroids preserve kidney function but have significant side effects. Newer immunosuppressive agents may have improved toxicity profiles... - Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic reviewGiovanni F M Strippoli
NHMRC Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, Children s Hospital at Westmead, Westmead, NSW 2145, Australia
BMJ 329:828. 2004..To evaluate the effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (AIIRAs) on renal outcomes and all cause mortality in patients with diabetic nephropathy... - Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trialsElisabeth M Hodson
National Health and Medical Research Council Centre for Clinical Research Excellence, Centre for Kidney Research, The Children s Hospital at Westmead, Sydney, Australia
Lancet 365:2105-15. 2005..We undertook a systematic review to investigate whether this approach affects risks of cytomegalovirus disease and death... - Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trialsGiovanni F M Strippoli
Centre for Kidney Research, National Health and Medical Research Council Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, Children s Hospital at Westmead, University of Sydney, Sydney, Australia
Am J Kidney Dis 44:591-603. 2004..Oral, nasal, and topical antibiotic prophylaxis; exit-site disinfectants; and other antimicrobial interventions are used to prevent it. This study was conducted to assess what evidence supports these approaches... - A pegylated epoetin in anaemia of renal disease: non-inferiority for an unvalidated surrogateRowan G Walker
North West Dialysis, Royal Melbourne Hospital, Melbourne, Vic, Australia
Lancet 370:1395-6. 2007 - A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective studyCarlo Manno
Department of Emergency and Organ Transplantation, Renal, Dialysis and Transplant Unit, University of Bari, Bari, Italy
Am J Kidney Dis 49:763-75. 2007..We evaluated factors associated with long-term renal survival by using a novel simplified histological classification... - The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trialAntonio Santoro
Nephrology, Dialysis, and Hypertension Department, Policlinico S Orsola Malpighi, Bologna, Italy
Am J Kidney Dis 52:507-18. 2008.... - Antihypertensive agents in patients with diabetes: trade-off between renal and cardiovascular protectionSankar D Navaneethan
Division of Nephrology, University of Rochester, 601 Elmwood Drive, Box 675, Rochester, NY 14642, USA
Diabetes Educ 32:596-602. 2006..Use of any agent that provides tight control of blood pressure is indicated in patients with diabetes but without nephropathy... - Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trialsSankar D Navaneethan
Department of Medicine, Unity Health System, Rochester, New York, United States of America
PLoS Med 3:e123. 2006 - Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic reviewKannaiyan S Rabindranath
Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK
Am J Kidney Dis 45:437-47. 2005.... - Hypothesis versus association: the optimal hemoglobin target debateGiovanni F M Strippoli
Am J Kidney Dis 46:970-3. 2005